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Purpose of the study
Besides its known effects on bone metabolism, vitamin D may regulate immune function. We performed a randomized
controlled trial (RCT) to test whether cholecalciferol supplementation can improve vitamin D status and modulate immune
responses in HIV-infected children and youth.
Methods
Caucasian vertically HIV-infected patients (aged 8 to 26 years) with vitamin D deficiency and normal parathormone (PTH) levels
were randomized into an experimental (n25) and control (n25) group to receive 100,000 IU of oral cholecalciferol every 3
months for a total of 4 doses, or placebo. A pre-randomization period (3 months) was also taken into account to better model
within-individual variability. Mixed linear regression models were used to evaluate the between-group changes in the outcomes
of interest. The analysis was intention to treat.
Summary of results
47 subjects completed the RCT. Cholecalciferol supplementation produced an early decrease in PTH levels (3 months) and a later
concomitant increase in 25(OH)D and 1,25(OH)2D levels (6 months), both persisting up to 12 months.
The supplementation had no effect on CD4T-cell numbers or percentage while was associated with a decreased
loge Th1, an increased loge Th2 (*pB0.05), an increased loge Treg (**pB0.01), and and a decreased loge Th17:Treg
(*pB0.05).
Conclusions
In our cohort, supplementation with oral cholecalciferol was effective in increasing serum 25(OH)D and 125(OH)2D while
decreasing serum PTH levels, had no effect on CD4T-cell count, but was associated with T-cell phenotype changes mainly
favoring Tregulatory subset.
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Loge VDR Loge Th1 Loge Th2 Loge (Th1:Th2) Loge Th17 Loge Treg Loge (Th17:Treg)
Month 3 0.5
(0.1 to 1.2)
1.6
(3.6 to 0.5)
0.1
(0.6 to 0.5)
1.4
(3.5 to 0.7)
1.5
(3.2 to 0.2)
0.6
(0.3 to 1.6)
2.5
(4.5 to0.4)*
Month 12 0.7
(3.0 to 1.7)
0.7
(2.5 to 1.1)
1.1*
(0.02 to 2.1)
1.6
(3.7 to 0.5)
0.3
(1.2 to 1.8)
1.7**
(0.6 to 2.7)
1.3
(3.3 to 0.7)
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